OBJECTIVES: Mucosal healing is important in celiac disease (CD) for the prevention of complications. However, obtaining duodenal biopsies is invasive, and there is currently no reliable surrogate marker for histological remission in clinical practice. We aimed to assess the role of a point-of-care test (POCT) based on IgA/IgG-deamidated gliadin peptide, in detecting persistent villous atrophy (VA) in CD. METHODS: We prospectively recruited patients with CD attending endoscopy for the assessment of histological remission. All patients had IgA-endomysial (EMA) antibodies, IgA-tissue transglutaminase (TTG) antibodies, and the POCT performed, and completed a validated dietary adherence questionnaire. A gastroscopy was performed in all patients, with four biopsies taken from the second part of the duodenum and one from the duodenal bulb. We compared the diagnostic performance of the surrogate markers against duodenal histology as the reference standard. RESULTS: A total of 217 patients with CD (70% female, age range 16-83 years, median age 53 years) on a gluten-free diet (median duration 6 years) were recruited from 2013 to 2017. Eighty-five (39.2%) patients had persistent VA. The sensitivities of the POCT, TTG, EMA, and the adherence score in detecting VA were 67.1%, 44.7%, 37.7%, and 24.7% respectively (P=0.0005). The combination of the POCT and adherence score only marginally increased the sensitivity to 70.6% (59.7-80.0%). CONCLUSIONS: The sensitivity of the POCT was higher than the other surrogate markers in predicting VA. A POCT may provide the additional advantage of an immediate objective assessment of mucosal healing at the time of an office-based follow-up consultation.
OBJECTIVES: Mucosal healing is important in celiac disease (CD) for the prevention of complications. However, obtaining duodenal biopsies is invasive, and there is currently no reliable surrogate marker for histological remission in clinical practice. We aimed to assess the role of a point-of-care test (POCT) based on IgA/IgG-deamidated gliadin peptide, in detecting persistent villous atrophy (VA) in CD. METHODS: We prospectively recruited patients with CD attending endoscopy for the assessment of histological remission. All patients had IgA-endomysial (EMA) antibodies, IgA-tissue transglutaminase (TTG) antibodies, and the POCT performed, and completed a validated dietary adherence questionnaire. A gastroscopy was performed in all patients, with four biopsies taken from the second part of the duodenum and one from the duodenal bulb. We compared the diagnostic performance of the surrogate markers against duodenal histology as the reference standard. RESULTS: A total of 217 patients with CD (70% female, age range 16-83 years, median age 53 years) on a gluten-free diet (median duration 6 years) were recruited from 2013 to 2017. Eighty-five (39.2%) patients had persistent VA. The sensitivities of the POCT, TTG, EMA, and the adherence score in detecting VA were 67.1%, 44.7%, 37.7%, and 24.7% respectively (P=0.0005). The combination of the POCT and adherence score only marginally increased the sensitivity to 70.6% (59.7-80.0%). CONCLUSIONS: The sensitivity of the POCT was higher than the other surrogate markers in predicting VA. A POCT may provide the additional advantage of an immediate objective assessment of mucosal healing at the time of an office-based follow-up consultation.
Authors: Gail G Pyle; Brian Paaso; Barbara E Anderson; Diane Allen; Thomas Marti; Chaitan Khosla; Gary M Gray Journal: Clin Gastroenterol Hepatol Date: 2005-07 Impact factor: 11.382
Authors: Peter D Mooney; Simon H Wong; Alexander J Johnston; Matthew Kurien; Anastasios Avgerinos; David S Sanders Journal: Clin Gastroenterol Hepatol Date: 2015-01-26 Impact factor: 11.382
Authors: D A George; L L Hui; D Rattehalli; T Lovatt; I Perry; M Green; K Robinson; J R F Walters; M J Brookes Journal: Frontline Gastroenterol Date: 2013-09-03
Authors: Benjamin Lebwohl; Karl Michaëlsson; Peter H R Green; Jonas F Ludvigsson Journal: J Clin Endocrinol Metab Date: 2014-01-16 Impact factor: 5.958
Authors: D A Leffler; J B Edwards George; M Dennis; E F Cook; D Schuppan; C P Kelly Journal: Aliment Pharmacol Ther Date: 2007-11-01 Impact factor: 8.171
Authors: Benjamin Lebwohl; Fredrik Granath; Anders Ekbom; Karin E Smedby; Joseph A Murray; Alfred I Neugut; Peter H R Green; Jonas F Ludvigsson Journal: Ann Intern Med Date: 2013-08-06 Impact factor: 25.391
Authors: Elizabeth G Bannister; Donald J Cameron; Jessica Ng; Chung W Chow; Mark R Oliver; George Alex; Anthony G Catto-Smith; Ralf G Heine; Annette Webb; Kathleen McGrath; Diane Simpson; Winita Hardikar Journal: Am J Gastroenterol Date: 2014-07-29 Impact factor: 10.864